Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their lead program in the ophthalmic pipeline, NCX 470, is currently in Phase 3 clinical development targeting glaucoma. Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251.

They have two products commercialized in the U.S.: VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% for open-angle glaucoma and ZERVIATE® (cetirizine ophthalmic solution) 0.24% for ocular allergic conjunctivitis. These products are being rolled out in territories outside of the U.S. through partnerships.

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop targeting glaucoma that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. The first of two Phase 3 trials for NCX 470, Mont Blanc, met the efficacy requirements for approval in the U.S. The similarly designed and ongoing second Phase 3 trial, Denali, conducted at clinical sites in the U.S. and China is ongoing with topline results are expected in H2 2025.

–  Therapeutic areas: Ophthalmology

–  Based in: Sophia Antipolis (FRANCE), Durham (USA)

–  Employees: 11 – 50

–  Created in: 1996